← Banking With Billy News

Atossa Therapeutics said it expects FDA IND clearance by early 2027 for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome. The Q3 update

BWB News TV • 2026-11-10 14:22 UTC • By Billy Odell Tucker-Robinson
Atossa Therapeutics said it expects FDA IND clearance by early 2027 for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome. The Q3 update
Atossa Therapeutics said it expects FDA IND clearance by early 2027 for (Z)-endoxifen in Duchenne muscular dystrophy and McCune-Albright syndrome. The Q3 update marks a broader push into rare diseases and unmet-need indications.
Share this article
𝕏 X / Twitter Facebook LinkedIn WhatsApp
📚 More from Billy’s World
📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly